Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recurrence is a serious problem in patients with bladder cancer. The hypothesis for recurrence was that the proliferation of drug-resistant cells was reported, and this study focused on drug resistance due to drug efflux. Previous studies have identified FOXM1 as the key gene for recurrence. We found that FOXM1 inhibition decreased drug efflux activity and increased sensitivity to Doxorubicin. Therefore, we examined whether the expression of ABC transporter gene related to drug efflux is regulated by FOXM1. As a result, ABCG2, one of the genes involved in drug efflux, has been identified as a new target for FOXM1. We also demonstrated direct transcriptional regulation of ABCG2 by FOXM1 using ChIP assay. Consequently, in the presence of the drug, FOXM1 is proposed to directly activate ABCG2 to increase the drug efflux activation and drug resistance, thereby involving chemoresistance of bladder cancer cells. Therefore, we suggest that FOXM1 and ABCG2 may be useful targets and important parameters in the treatment of bladder cancer.
Abstract
Recurrence is a serious problem in patients with bladder cancer. The hypothesis for recurrence was that the proliferation of drug-resistant cells was reported, and this study focused on drug resistance due to drug efflux. Previous studies have identified FOXM1 as the key gene for recurrence. We found that FOXM1 inhibition decreased drug efflux activity and increased sensitivity to Doxorubicin. Therefore, we examined whether the expression of ABC transporter gene related to drug efflux is regulated by FOXM1. As a result, ABCG2, one of the genes involved in drug efflux, has been identified as a new target for FOXM1. We also demonstrated direct transcriptional regulation of ABCG2 by FOXM1 using ChIP assay. Consequently, in the presence of the drug, FOXM1 is proposed to directly activate ABCG2 to increase the drug efflux activation and drug resistance, thereby involving chemoresistance of bladder cancer cells. Therefore, we suggest that FOXM1 and ABCG2 may be useful targets and important parameters in the treatment of bladder cancer.
참고문헌 (31)
- Torre LA, "Global cancer statistics,2012", CA Cancer J Clin, 65, pp.87~108 (2015)[DOI]
- Youssef RF, "Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer", ScientificWorldJournal, 11, pp.369~381 (2011)[DOI]
- Sylvester RJ, "Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials", Eur Urol, 49, pp.466~465 (2006)[DOI]
- Hall MC, "Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update", J Urol, 178, pp.2314~2330 (2007)[DOI]
- Woldu SL, "Guideline of guidelines: non-muscle-invasive bladder cancer", BJU Int, 119, pp.371~380 (2017)[DOI]
- van Rhijn BW, "Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy", Eur Urol, 56, pp.430~442 (2009)[DOI]
- Chen Y, "FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence", Tumour Biol, 37, pp.4313~4321 (2016)[DOI]
- Chang JC, "Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance", Medicine (Baltimore), 95, pp.S20~S25 (2016)[DOI]
- Salehan MR, "DNA damage repair and tolerance: a role in chemotherapeutic drug resistance", Br J Biomed Sci, 70, pp.31~40 (2013)[DOI]
- 류진현, "Resveratrol Induces Glioma Cell Apoptosis through Activation of Tristetraprolin", Molecules and Cells, 38(11), pp.991~997 (2015), 한국분자세포생물학회
- Millour J, "ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance", Mol Cancer Ther, 10, pp.1046~1058 (2011)[DOI]
- Rosenfeldt MT, "E2F1 drives chemotherapeutic drug resistance via ABCG2", Oncogene, 33, pp.4164~4172 (2014)[DOI]
- Costa RH, "FoxM1 dances with mitosis", Nat Cell Biol, 7, pp.108~110 (2005)[DOI]
- Kim SK, "Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer", Clin Cancer Res, 20, pp.3233~3243 (2014)[DOI]
- Park YY, "FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair", Carcinogenesis, 33, pp.1843~1853 (2012)[DOI]
- Nestal de Moraes G, "Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance", Curr Drug Targets, 17, pp.164~177 (2016)[DOI]
- Khongkow P, "Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance", Oncogene, 35, pp.990~1002 (2016)[DOI]
- Gemenetzidis E, "Induction of human epithelial stem", progenitor expansion by FOXM1, 2010, pp.70, 9515~9526
- Zahreddine H, "Mechanisms and insights into drug resistance in cancer", Front Pharmacol, 4, pp.28~ (2013)
- Fletcher JI, "ABC transporters in cancer: more than just drug efflux pumps", Nat Rev Cancer, 10, pp.147~156 (2010)[DOI]
- Ding XW, "ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy", Life Sci, 86, pp.631~637 (2010)[DOI]
- Mo W, "Human ABCG2: structure, function, and its role in multidrug resistance", Int J Biochem Mol Biol, 3, pp.1~27 (2012)
- An Y, "ABCG2: the key to chemoresistance in cancer stem cells?", Expert Opin Drug Metab Toxicol, 5, pp.1529~1542 (2009)[DOI]
- Robey RW, "ABCG2: a perspective", Adv Drug Deliv Rev, 61, pp.3~13 (2009)[DOI]
- Guzel E, "Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer", Prostate, 74, pp.1498~1505 (2014)[DOI]
- Hu J, "Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes", Oncotarget, 8, pp.28463~28470 (2017)
- Costa C, "Abnormal Protein Glycosylation and Activated PI3K", Akt, PLoS One, pp.2015, 10[DOI]
- Natarajan K, "Role of breast cancer resistance protein (BCRP", ABCG2) in cancer drug resistance, 2012, pp.83, 1084~1103
- Teh MT, "FOXM1 coming of age: time for translation into clinical benefits?", Front Oncol, 2, pp.146~ (2012)
- Damiani D, "ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome", Am J Hematol, 90, pp.784~789 (2015)[DOI]
- Kim DH, "The E2F1 oncogene transcriptionally regulates NELL2 in cancer cells", DNA Cell Biol, 32, pp.517~523 (2013)[DOI]